Hospital pharmacists compounding medications for their own patients are accustomed to routine inspections from state boards of pharmacy and accrediting bodies like the Joint Commission. However, a growing number of hospital compounding operations are drawing attention from a different, more powerful regulator: the FDA. Understanding whether your pharmacy operates as a 503A facility or could benefit from a 503B outsourcing partnership, and what distinguishes the two, is the first step toward managing that risk and developing an effective sterile compounding strategy.
What is a 503A pharmacy?
503A refers to the section of the Federal Food, Drug, and Cosmetic Act governing traditional pharmacy compounding: patient-specific prescriptions, compounded by a licensed pharmacist for an individual patient based on a valid order. 503A pharmacies are regulated primarily at the state level by boards of pharmacy under USP <795> and <797> standards, though the FDA retains oversight authority and has increasingly exercised it for hospital pharmacies compounding at scale.
What is a 503B outsourcing facility?
503B outsourcing facilities are a category the FDA created through the 2013 Drug Quality and Security Act (DQSA). Unlike 503A pharmacies, 503B facilities are FDA-registered, produce sterile medications in large batches without patient-specific prescriptions, and operate under current Good Manufacturing Practice (cGMP) requirements, a materially more rigorous standard than most 503A operations, including routine FDA inspection as a condition of registration.
Key differences
| 503A Pharmacy | 503B Outsourcing Facility | |
| Primary regulator | State board of pharmacy | FDA (registered facility) |
| Prescription requirement | Patient-specific | Not required — bulk/anticipatory compounding |
| Quality standard | USP <795> / <797> | cGMP |
| Inspection | State board, periodic | FDA, routine |
| Typical batch size | Small, per-patient | Large-scale |
| Beyond-use dating | Generally shorter | Generally longer |
Why the distinction matters for FDA inspection risk
Hospitals that compound at scale in-house, producing standardized batches without individual prescriptions, can begin to resemble 503B manufacturing in practice, even while remaining registered and operating as 503A facilities. This distinction is precisely what has drawn increased FDA attention to hospital compounding operations in recent years. Partnering with a registered 503B outsourcing facility can help shift that regulatory burden and inspection exposure to a partner specifically equipped to manage it, while allowing your in-house pharmacy to remain focused on patient-specific compounding.
How to know which one your hospital needs
Most health systems use both: a 503A pharmacy (in-house or affiliated) for patient-specific compounding, and a 503B outsourcing partner for the anticipatory, large-batch, ready-to-administer medications that would otherwise strain in-house capacity or introduce compliance risk. If your pharmacy is compounding in bulk, managing frequent drug shortages, or facing space and cost constraints meeting cGMP-level infrastructure, that's a signal to evaluate a 503B outsourcing relationship.
Quva is an FDA-registered 503B outsourcing facility, compounding sterile medications under cGMP requirements at the scale hospitals need to stay ahead of shortages. See our 503B outsourcing overview to learn more, or use our 503B outsourcing facility checklist to evaluate any outsourcing partner - including Quva.
FAQs:
